Does targeted therapy treat polycythaemia vera?

Polycythaemia vera is a blood disorder in which the bone marrow makes too many blood cells, particularly red blood cells. This can make blood more prone to flow slowly or form clots. A targeted medicine may act on a signalling pathway involved in the marrow's abnormal activity.

Treatment aims to control the disorder and lower risks linked with excess blood cells. A haematologist may consider targeted therapy alongside other approaches, depending on blood counts, symptoms, clotting history, age, general health, and response to earlier treatment. It is not suitable for every person with polycythaemia vera.

Discuss the reason a targeted medicine is being suggested and whether it is intended to control blood counts, ease symptoms, or address resistance or intolerance to another approach. Ask how often blood tests are needed and which results guide dose changes.

Take the medicine exactly as prescribed and tell the haematology team about new medicines, supplements, pregnancy plans, or troublesome effects. Do not change treatment on your own, even if a blood count improves.

Seek emergency care for sudden weakness on one side, trouble speaking, severe chest pain, sudden breathlessness, or a painful swollen limb, as these may signal a clot. Contact your haematology team promptly for fever, unusual bleeding, severe headache, vision changes, or a new painful redness in the skin.

What feature of my polycythaemia vera makes targeted therapy suitable? What blood counts and symptoms will we monitor? What should I do if I miss a dose? Which warning signs require emergency care, and how can I reach the team after hours?